



ON-DEMAND, AUDIO ONLY BUPRENORPHINE TELEHEALTH

ASAM 2022 Policy and Science Plenary

#ASAMAnnual2022

Disclosure Information

Rachel S. Wightman, MD, FACMT

On-Demand, Audio Only Buprenorphine Telehealth

Saturday, April 2, 2022 8:30 – 10:00 AM


No Disclosures



- Telephone only
- Bridge clinic
- On-demand 24/7
- Initiate buprenorphine treatment
- Link to a provider
- Staffed by six providers
- Do not bill for telephone visit

HOTLINE KEY FACTS

Drug Overdose Mortality by State





Why Telephone Only?

- Provide low-threshold buprenorphine access
- Fill gaps in care to meet patient needs on-demand
- Improve equity in addiction treatment




Who's Calling? 4/20 – 2/21

- 60% male, mean age 40
- Majority of callers in opioid withdrawal
- Majority of callers have prior addiction treatment experience; 7.6% in treatment at time of call
- 2/3 of callers had taken buprenorphine previously – prescribed and/or non-prescribed
- 1/3 had filled a prior buprenorphine prescription in the year preceding the call

STATS AND FOLLOW-UP: 4/20 TO 2/21



- 131 unique callers
- 125 connected to an X-waivered provider



- 98 prescriptions (74%)
- 92 filled prescriptions (94%)



- 71% (65/92) 30 day Rx
- On average 5.5 days (range 0-27) after initial Rx

Opportunities

- Accessible care in a 24/7 world
- Bypass barriers to treatment (stigma, transportation, geography, etc.)
- Fill gaps in treatment access; serves as an entry point to care
- Channel to disseminate harm reduction and community resources



Challenges

- Scale outside of small, dense area
- Narrowness of services provided
- Sustainability (currently grant funded, not billing)
- Regulatory uncertainty

REFERENCES

1. Samuels, E. , Clark, S. , Wunsch, C. , Jordison Keeler, L. , Reddy, N. , Vanjani, R. & Wightman, R. (2020). Innovation During COVID-19: Improving Addiction Treatment Access. *Journal of Addiction Medicine*, 14 (4), e8-e9. doi: 10.1097/ADM.0000000000000685.
2. Fischer SH, Ray KN, Mehrotra A, Bloom EL, Uscher-Pines L. Prevalence and Characteristics of Telehealth Utilization in the United States. *JAMA Netw Open*. 2020;3(10):e2022302. doi:10.1001/jamanetworkopen.2020.22302
3. Eberly LA, Kallan MJ, Julien HM, et al. Patient Characteristics Associated With Telemedicine Access for Primary and Specialty Ambulatory Care During the COVID-19 Pandemic. *JAMA Netw Open*. 2020;3(12):e2031640. doi:10.1001/jamanetworkopen.2020.31640
4. Uscher-Pines L, Sousa J, Jones M, et al. Telehealth Use Among Safety-Net Organizations in California During the COVID-19 Pandemic. *JAMA*. 2021;325(11):1106–1107. doi:10.1001/jama.2021.0282
5. Bauerly BC, McCord RF, Hulkower R, Pepin D. Broadband Access as a Public Health Issue: The Role of Law in Expanding Broadband Access and Connecting Underserved Communities for Better Health Outcomes. *J Law Med Ethics*. 2019;47(2_suppl):39-42. doi:10.1177/1073110519857314
6. Wunsch C, Lum L, Wightman RS, Pratty C, Jacka B, Hallowell B, Clark S, Samuels EA. On-Demand, Audio-only Buprenorphine Initiation During Covid-19. Accepted abstract ASAM 2022.
7. Samuels, E.A., Khatri, U.G., Snyder, H. et al. Buprenorphine Telehealth Treatment Initiation and Follow-Up During COVID-19. *J GEN INTERN MED* (2022). <https://doi.org/10.1007/s11606-021-07249-8>
8. Yeo, E.J., Krallies, H., Sternberg, D. et al. Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.. *Harm Reduct J* 18, 127 (2021). <https://doi.org/10.1186/s12954-021-00578-1>
9. Weintraub E, Seneviratne C, Anane J, et al. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder. *JAMA Netw Open*. 2021;4(8):e2118487. doi:10.1001/jamanetworkopen.2021.18487